Ionis Pharmaceuticals (IONS)
Develops antisense medicines through owned launches and pharmaceutical partnerships.
$45.39
vs last close+0.49 (+1.10%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 106.48% | 176.94M shares | |
|---|---|---|---|
| 556 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.76% | 1.27M shares | |
| 21 holders · as of Sep 2, 2026 | |||
| Strategic holders | 6.92% | 11.50M shares | |
| 1 holder · as of Jun 7, 2018 | |||
| Adds to | 114.16% | ||
166.18M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 114.16%; nothing is left for Other.
13F, as of Jun 30, 2026
556 holders · 176.94M shares · 70 new positions · 278 increased · 153 reduced · 45 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 24.63M | 14.82% | +75.3K | Aug 13, 2026 |
| Capital World Investors | 21.67M | 13.04% | +482.9K | Aug 12, 2026 |
| BlackRock, Inc. | 10.70M | 6.44% | +262.2K | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 7.86M | 4.73% | +50.6K | Aug 13, 2026 |
| Wellington Management Group LLP | 7.65M | 4.60% | +1.26M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 7.21M | 4.34% | +93.2K | Aug 13, 2026 |
| Two Sigma Investments, LP | 6.25M | 3.76% | +394.7K | Aug 14, 2026 |
| Royal Bank of Canada | 6.18M | 3.72% | +2.38M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Capital World Investors | 12.80% | 21.19M | 13G | May 14, 2026 |
| Wellington Group Holdings LLPincl. Wellington Management Company LLP, Wellington Investment Advisors Holdings LLP +1 more | 5.76% | 9.07M | 13G | Nov 8, 2024 |
| BlackRock, Inc. | 5.70% | 9.07M | 13G | Apr 17, 2025 |
| Vanguard Capital Management | 5.05% | 8.34M | 13G | Apr 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 30, 2026 | Michael R. Haydendirector | Purchase | 15,000 | $53.38 | 19,000 |
| Jul 31, 2026 | Michael R. Haydendirector | Purchase | 5,000 | $51.60 | 24,000 |
| Jul 7, 2026 | Holly B. Kordasiewiczofficer: EVP, Chief Development Officer | Sale | 362 | $84.30 | 22,096 |
| Jul 7, 2026 | Allene M. Diazdirector | Sale | 10,111 | $85.42 | 3,811 |
| Jul 7, 2026 | C. Frank Bennettofficer: EVP, Chief Scientific Officer | Sale · 2 lots | 20,536 | $84.95 | 75,018 |
| Jul 1, 2026 | Joseph Iii Kleindirector | Sale · 2 lots | 11,518 | $79.04 | 11,014 |
| Jun 26, 2026 | Eugene Schneiderofficer: EVP, Chf Clinical Develop Ofcr | Sale | 26,000 | $81.05 | 77,114 |
| Jun 26, 2026 | Patrick R. O'Neilofficer: EVP CLO & General Counsel | Sale | 3,069 | $80.00 | 61,470 |
| Jun 26, 2026 | Joseph Baroldiofficer: EVP, Chief Business Officer | Sale | 5,635 | $80.16 | 4,669 |
| Jun 25, 2026 | Eric Swayzeofficer: EVP Research | Sale | 10,602 | $79.18 | 21,759 |
House and Senate disclosures
Not reported.